The supply of GLP-1 drugs has been increasing, but they’re still expensive for most patients. Here are answers to some ...

"We are introducing Wegovy (injectable Semaglutide 2.4 mg) this year, which offers full therapeutic strengths of semaglutide ...

The Danish company’s controlling shareholder, the Novo Nordisk Foundation, had pushed him to step down after the share price ...

Goldman Sachs lowered its forecast for the total market for anti-obesity drugs through the end of the decade. Asad Haider, ...

Tirzepatide, the newest weight loss drug in India, is transforming the wellness market with its hormone-mimicking effects.

Novo's Wegovy has lost market share to Eli Lilly's Zepbound, and a new head-to-head study found that Zepbound patients lost ...

Eli Lilly & Co. said Tuesday it’s cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity for patients who have to pay for the drug themselves. It said it will ...

Growing demand for natural weight loss solutions drives the weight management supplements market across health-conscious consumer segments.

Over the past six months, Eli Lilly has earned significant wins over its Denmark-based rival and is still at it. Recent clinical trial results Eli Lilly released suggest that it is building a lead in ...

Ozempic made headlines. Now its maker faces stock crashes, CEO fallout, and fierce rivalry from Eli Lilly. Discover the trade behind the drama.

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

A miracle drug just wiped out WeightWatchers International’s (WW) 60-year empire. Here’s how Ozempic disrupted the weight ...